The Johns Hopkins Cancer Center is dedicated to research and education in cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. This application requests continued CCSG support for the Johns Hopkins Cancer Center's research programs and shared resources. The Johns Hopkins Cancer Center is a multidisciplinary, interdepartmental institute of the Johns Hopkins University. There is a broad base of ongoing cancer research at Johns Hopkins. The special scientific programs of the Cancer Center are interdisciplinary in character and are focused on human disease. A wide range of activity is encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new antitumor treatments. The six major research programs of the Center are: Cancer Biology (Baylin), Hematologic Malignancies (Grever), Urologic Oncology (Coffey), Gastrointestinal Cancer (Hamilton), Cancer Prevention and Control (Groopman), Solid Tumor Research (Donehower). There is one developing program in Breast Cancer Research (Davidson). Sixteen Shared Resources currently support the needs of Center investigators. Electron Microscopy, Flow Cytometry, Experimental Irradiators, Animal Resources, Facilities and Common Equipment, Glassware Washing, Human Tissue and Pathology, Cytogenetics and Molecular Genetics, Graft Engineering, Pharmacologic Analytic, Biostatistics, Clinics Research Office, Research Pharmacy and Research Nursing are existing CCSG funded CORES. We are also asking for support for two new resources, the Genetics Research CORE and Research Computing. Interdisciplinary research seminars and research training programs provide valuable opportunities for interdisciplinary interaction and collaboration. Cancer Center developmental funds are used to support faculty recruitment and innovative research. Special emphasis is placed on pilot projects that have the potential for peer-reviewed funded translational research, innovative clinical trials, methodology research and interdisciplinary initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006973-38S1
Application #
6348763
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Silkensen, Shannon M
Project Start
1978-01-01
Project End
2001-04-30
Budget Start
2000-07-25
Budget End
2001-04-30
Support Year
38
Fiscal Year
2000
Total Cost
$380,645
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications